Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on PAHC shares. TheStreet raised Phibro Animal Health from a "c+" rating to a "b-" rating in a research note on Friday, July 29th. StockNews.com cut Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 5th. Finally, Barclays cut Phibro Animal Health from an "equal weight" rating to an "underweight" rating and set a $22.00 price target on the stock. in a research note on Monday, July 25th.
Phibro Animal Health Trading Up 2.5 %
Shares of PAHC Stock traded up $0.46 during trading hours on Friday, reaching $19.20. The company's stock had a trading volume of 69,993 shares, compared to its average volume of 90,844. The stock has a market capitalization of $777.68 million, a P/E ratio of 13.24 and a beta of 0.51. Phibro Animal Health has a one year low of $17.28 and a one year high of $26.55. The firm's fifty day simple moving average is $19.20 and its 200 day simple moving average is $19.46. The company has a current ratio of 2.92, a quick ratio of 1.59 and a debt-to-equity ratio of 1.50.
Phibro Animal Health Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 28th. Investors of record on Wednesday, September 7th will be given a dividend of $0.12 per share. The ex-dividend date is Tuesday, September 6th. This represents a $0.48 annualized dividend and a dividend yield of 2.50%. Phibro Animal Health's dividend payout ratio is presently 33.10%.